Anavex Life Sciences Corp (AVXL)

[nor377]

Below you can see three licensing deals by Biogen that had much larger up front payments:
From Fierce Bio JPM Week
That said, all three of Biogen's deals—with Sage, Sangamo and Denali Therapeutics, worth around $8 billion altogether—are high risk, too, given the challenges of operating in neurosciences. A hefty $2.8 billion of that total was paid upfront.